Spero Therapeutics, Inc. (SPRO): Price and Financial Metrics

Spero Therapeutics, Inc. (SPRO): $0.83

0.09 (+11.66%)

POWR Rating

Component Grades














  • Value is the dimension where SPRO ranks best; there it ranks ahead of 47.95% of US stocks.
  • SPRO's strongest trending metric is Growth; it's been moving down over the last 179 days.
  • SPRO's current lowest rank is in the Momentum metric (where it is better than 4.64% of US stocks).

SPRO Stock Summary

  • Spero Therapeutics Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 14.29% of US listed stocks.
  • For SPRO, its debt to operating expenses ratio is greater than that reported by merely 12.43% of US equities we're observing.
  • With a price/sales ratio of 15.25, Spero Therapeutics Inc has a higher such ratio than 90.7% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Spero Therapeutics Inc, a group of peers worth examining would be APM, PRTC, LOGC, LCTX, and BLDP.
  • SPRO's SEC filings can be seen here. And to visit Spero Therapeutics Inc's official web site, go to sperotherapeutics.com.

SPRO Valuation Summary

  • In comparison to the median Healthcare stock, SPRO's EV/EBIT ratio is 124.91% lower, now standing at -7.3.
  • Over the past 47 months, SPRO's price/sales ratio has gone down 179.1.
  • Over the past 47 months, SPRO's price/sales ratio has gone down 179.1.

Below are key valuation metrics over time for SPRO.

Stock Date P/S P/B P/E EV/EBIT
SPRO 2021-08-31 33.7 6.9 -8.2 -7.3
SPRO 2021-08-30 31.6 6.4 -7.7 -6.8
SPRO 2021-08-27 29.7 6.0 -7.2 -6.4
SPRO 2021-08-26 29.1 5.9 -7.1 -6.2
SPRO 2021-08-25 29.6 6.0 -7.2 -6.4
SPRO 2021-08-24 28.4 5.8 -6.9 -6.1

SPRO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SPRO has a Quality Grade of C, ranking ahead of 28.84% of graded US stocks.
  • SPRO's asset turnover comes in at 0.128 -- ranking 241st of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows SPRO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.128 1 -1.651
2021-03-31 0.108 1 -1.872
2020-12-31 0.072 1 -2.390
2020-09-30 0.094 1 -2.720
2020-06-30 0.110 1 -2.104
2020-03-31 0.108 1 -1.684

SPRO Price Target

For more insight on analysts targets of SPRO, see our SPRO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $38.17 Average Broker Recommendation 1.58 (Moderate Buy)

SPRO Stock Price Chart Interactive Chart >

Price chart for SPRO

SPRO Price/Volume Stats

Current price $0.83 52-week high $19.87
Prev. close $0.74 52-week low $0.73
Day low $0.74 Volume 218,100
Day high $0.84 Avg. volume 470,242
50-day MA $1.89 Dividend yield N/A
200-day MA $10.21 Market Cap 27.16M

Spero Therapeutics, Inc. (SPRO) Company Bio

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. It is developing SPR994, an oral carbapenem-class antibiotic for use in adults to treat MDR gram-negative infections; SPR741 that has completed Phase I clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is in preclinical development stage to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic that is in preclinical development stage for the treatment of pulmonary non-tuberculous mycobacterial infections. The company was founded in 2013 and is based in Cambridge, Massachusetts.

SPRO Latest News Stream

Event/Time News Detail
Loading, please wait...

SPRO Latest Social Stream

Loading social stream, please wait...

View Full SPRO Social Stream

Latest SPRO News From Around the Web

Below are the latest news stories about Spero Therapeutics Inc that investors may wish to consider to help them evaluate SPRO as an investment opportunity.

Spero Therapeutics (SPRO) Gets a Buy Rating from Berenberg Bank

In a report released today, Esther Hong from Berenberg Bank maintained a Buy rating on Spero Therapeutics (SPRO – Research Report), with a price target of $44.00. The company's shares closed last Wednesday at $9.35. According to TipRanks.com, Hong is ranked 0 out of 5 stars with an average return of -23.0% and a 20.8% success rate. Hong covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Aldeyra Therapeutics, and Aprea Therapeutics. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Spero Therapeutics with a $44.00 average price target, representing a 331.8% upside.

Catie Powers on TipRanks | February 16, 2022

Spero Therapeutics antibiotic SPR206 shows promise in phase 1 trial

Spero Therapeutics (SPRO) reported positive results from a phase 1 trial of its antibiotic SPR206 to treat serious multi-drug resistant ((MDR)) gram-negative infections in the…

Seeking Alpha | February 16, 2022

Spero Therapeutics Sees Positive Topline Results for Antibiotic Trial

By Chris Wack Spero Therapeutics Inc. said it saw positive topline findings from its Phase 1 bronchoalveolar lavage clinical trial of SPR206, an…

MarketWatch | February 16, 2022

Spero Therapeutics Announces Positive Topline Results from Phase 1 Bronchoalveolar Lavage Clinical Trial of SPR206, A Novel Intravenous Next Generation Polymyxin Antibiotic for the Treatment of Multi-drug Resistant Gram-Negative Infections in the Hospital Setting

SPR206 shown to be well-tolerated; achieved lung exposures consistent with predicted therapeutic levels, when administered three times daily at 100 mg Results support further development of SPR206 in the setting of hospital-acquired pneumonia and ventilator-associated pneumonia CAMBRIDGE, Mass., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced topline findings from its Phase 1 bronchoalveolar lavage (BAL) clinical trial of SPR206, an intravenously (IV)-a

Yahoo | February 16, 2022

The past year for Spero Therapeutics (NASDAQ:SPRO) investors has not been profitable

It's easy to match the overall market return by buying an index fund. Active investors aim to buy stocks that vastly...

Yahoo | February 10, 2022

Read More 'SPRO' Stories Here

SPRO Price Returns

1-mo -20.19%
3-mo -87.85%
6-mo -94.43%
1-year -94.74%
3-year -93.05%
5-year N/A
YTD -94.82%
2021 -17.43%
2020 101.66%
2019 56.34%
2018 -47.66%
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.522 seconds.